Abstract
Several clinical trials have attempted to treat sepsis by blocking certain aspects of the inflammatory response. Tumor necrosis factor and interleukin 1 have been specific targets for inhibition but none of the trials have been successful. These trials were started on the basis of preclinical trials that suggested these would be effective. There were three lines of evidence to support the idea of cytokine inhibition. First, patients with increased levels of cytokines are more likely to die. Second, experimental animal models demonstrated that blocking the cytokines would improve outcome. Third, injection of purified, recombinant cytokines would cause both organ injury and death in experimental animals. Several additional aspects of the inflammatory response have been discovered since these trials were initiated. Included among these potential new targets are interleukin 18 and HMG-1. However, before new clinical trials are started there must be careful consideration of why previous interventions were not effective. The concept of blocking a single elevated cytokine may be too simple to deal with the complex problem of sepsis. As patients move through different phases of the septic response, there may be intervals when it is appropriate to inhibit multiple cytokines while at other times it may be appropriate to augment the immune response.
Keywords: Cytokine, immune response, Tumor, interleukin
Current Pharmaceutical Design
Title: Cytokine Therapeutics for the Treatment of Sepsis: Why has Nothing Worked?
Volume: 9 Issue: 1
Author(s): Daniel G. Remick
Affiliation:
Keywords: Cytokine, immune response, Tumor, interleukin
Abstract: Several clinical trials have attempted to treat sepsis by blocking certain aspects of the inflammatory response. Tumor necrosis factor and interleukin 1 have been specific targets for inhibition but none of the trials have been successful. These trials were started on the basis of preclinical trials that suggested these would be effective. There were three lines of evidence to support the idea of cytokine inhibition. First, patients with increased levels of cytokines are more likely to die. Second, experimental animal models demonstrated that blocking the cytokines would improve outcome. Third, injection of purified, recombinant cytokines would cause both organ injury and death in experimental animals. Several additional aspects of the inflammatory response have been discovered since these trials were initiated. Included among these potential new targets are interleukin 18 and HMG-1. However, before new clinical trials are started there must be careful consideration of why previous interventions were not effective. The concept of blocking a single elevated cytokine may be too simple to deal with the complex problem of sepsis. As patients move through different phases of the septic response, there may be intervals when it is appropriate to inhibit multiple cytokines while at other times it may be appropriate to augment the immune response.
Export Options
About this article
Cite this article as:
Remick G. Daniel, Cytokine Therapeutics for the Treatment of Sepsis: Why has Nothing Worked?, Current Pharmaceutical Design 2003; 9 (1) . https://dx.doi.org/10.2174/1381612033392567
DOI https://dx.doi.org/10.2174/1381612033392567 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coffee and Depression: A Short Review of Literature
Current Pharmaceutical Design The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics Pharmacological Modulation of Th17
Recent Patents on Inflammation & Allergy Drug Discovery Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets Growth Velocity, Final Height and Bone Mineral Metabolism of Short Children Treated Long Term with Growth Hormone
Current Pharmaceutical Biotechnology Polyphenols: Well Beyond The Antioxidant Capacity: Polyphenol Supplementation and Exercise-Induced Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Biomedical Technologies for In Vitro Screening and Controlled Delivery of Neuroactive Compounds
Central Nervous System Agents in Medicinal Chemistry Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Review of Childhood Obesity (Balar Athidhoola Rogam) in Traditional Siddha Indian Medicine
Current Traditional Medicine A Review of Current Knowledge of the Complement System and the Therapeutic Opportunities in Inflammatory Arthritis
Current Medicinal Chemistry Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice
CNS & Neurological Disorders - Drug Targets Cytosine Methyltransferases as Tumor Markers
Current Genomics Aberrant DNA Methylation and Prostate Cancer
Current Genomics Patent Selections:
Recent Patents on Biotechnology Getting Rid of Intracellular Aβ - Loss of Cellular Degradation Leads to Transfer Between Connected Neurons
Current Pharmaceutical Design Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.
Current Cancer Drug Targets Impaired Insulin Sensitivity and Secretion in Patients with Alzheimer’s Disease: The Relationship with Other Atherosclerosis Risk Factors
Current Vascular Pharmacology Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews